Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline
December 07 2016 - 8:00AM
Business Wire
-- Experienced communications
professional Susan Hubbard joins as Executive Vice President of
Public Affairs and Investor Relations --
-- Oncology business development executive
Stefan Krauss joins as Vice President of Business Development
--
Exelixis, Inc. (NASDAQ:EXEL) today announced two high-level
appointments designed to further strengthen the company’s public
affairs and business development capabilities following the launch
of its newest medicine, CABOMETYX™, earlier this year. Susan
Hubbard has joined the company as Executive Vice President of
Public Affairs and Investor Relations, and Stefan Krauss, Ph.D. has
joined as Vice President of Business Development.
“The regulatory approval and launch of CABOMETYX earlier this
year has provided a strong foundation for the next phase of
Exelixis’ growth,” said Michael M. Morrissey, Ph.D., President and
Chief Executive Officer at Exelixis. “In welcoming Susan and Stefan
to Exelixis, we are positioning the company for a transformational
period, and we are confident that their unique expertise will
strengthen our ability to advance the company as it continues to
evolve.”
As EVP of Public Affairs and Investor Relations, Susan Hubbard
will oversee the company’s public affairs, advocacy and investor
relations functions as a member of the company’s executive
leadership team. Prior to joining Exelixis in a full-time capacity,
Ms. Hubbard served as an independent public affairs and investor
relations consultant to the biopharmaceutical industry. From 2014
onward, she was instrumental in developing Exelixis’ communications
strategy around the late-stage clinical development, approval and
commercial launch of CABOMETYX, as well as several major milestones
for the company’s partnered programs. Previously, as one of the
initial employees at Gilead Sciences she spent over two decades in
roles of increasing responsibility, finishing her tenure as Vice
President of Investor Relations. She received her undergraduate
degree from University of California, Los Angeles.
As Vice President of Business Development, Stefan Krauss, Ph.D.
will lead Exelixis’ business development activities and its ongoing
partnering and in-licensing initiatives as the company seeks to
expand its pipeline of oncology therapeutics. Before joining
Exelixis, from 2014 to 2016 Dr. Krauss served as a Senior Director
of Business Development and Licensing at Baxalta (formerly Baxter
Bioscience). At Baxalta, he led oncology business development for
the company’s newly-formed Oncology Division and was instrumental
in adding transformational and innovative partnerships to the
company’s rapidly growing oncology portfolio. Prior to that, from
2011 to 2014 Dr. Krauss served as Director of Search and Evaluation
Oncology in the Global Business Development unit of EMD Serono,
where he identified and evaluated strategic oncology and
immuno-oncology in-licensing opportunities for the company.
Previously, Dr. Krauss held positions of increasing responsibility
at Merck Research Laboratories as a senior scientist and team
leader as well as in scientific business development, most recently
as a Senior Manager and Research Fellow, Global External Basic
Research (Oncology). Before entering the pharmaceutical industry,
Dr. Krauss was a Research Fellow in Medicine at Beth Israel
Deaconess Medical Center and Harvard Medical School. He holds both
M.Phil. and Ph.D. degrees in biochemistry from the University of
Cambridge (UK).
The new appointments underscore the company’s growth trajectory
and will further Exelixis’ efforts in addressing increased interest
from media, investors and potential partners.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company
committed to the discovery, development and commercialization of
new medicines with the potential to improve care and outcomes for
people with cancer. Since its founding in 1994, three medicines
discovered at Exelixis have progressed through clinical development
to receive regulatory approval. Currently, Exelixis is focused on
advancing cabozantinib, an inhibitor of multiple tyrosine kinases
including MET, AXL and VEGF receptors, which has shown clinical
anti-tumor activity in more than 20 forms of cancer and is the
subject of a broad clinical development program. Two separate
formulations of cabozantinib have received regulatory approval to
treat certain forms of kidney and thyroid cancer and are marketed
for those purposes as CABOMETYX™ tablets (U.S. and EU) and
COMETRIQ® capsules (U.S. and EU), respectively. Another
Exelixis-discovered compound, COTELLIC® (cobimetinib), a selective
inhibitor of MEK, has been approved in major territories including
the United States and European Union, and is being evaluated for
further potential indications by Roche and Genentech (a member of
the Roche Group) under a collaboration with Exelixis. For more
information on Exelixis, please visit www.exelixis.com or follow
@ExelixisInc on Twitter.
Forward-Looking Statements
This press release contains forward-looking statements,
including, without limitation, statements related to: the impact of
the two high-level appointments on the strength of Exelixis’ public
affairs and business development capabilities, and the ability to
advance the company as it continues to evolve; the next phase of
Exelixis’ growth; Exelixis’ plans to seek to expand its pipeline of
oncology therapeutics; Exelixis’ growth trajectory; Exelixis'
commitment to the discovery, development and commercialization of
new medicines with the potential to improve care and outcomes for
people with cancer; Exelixis’ focus on advancing cabozantinib; and
the continued development of cobimetinib. Words such as “further,”
“next,” “will,” “continue,” “committed,” “focused,” “potential,” or
other similar expressions identify forward-looking statements, but
the absence of these words does not necessarily mean that a
statement is not forward-looking. In addition, any statements that
refer to expectations, projections or other characterizations of
future events or circumstances are forward-looking statements.
These forward-looking statements are based upon Exelixis’ current
plans, assumptions, beliefs, expectations, estimates and
projections. Forward-looking statements involve risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in the forward-looking statements
as a result of these risks and uncertainties, which include,
without limitation: Exelixis’ ability to successfully address
increasing interest from media, investors and potential partners;
Exelixis’ ability to enter into future collaborations on acceptable
terms; the risk that unanticipated developments could adversely
affect the commercialization of CABOMETYX or COMETRIQ; Exelixis’
ability to conduct clinical trials of cabozantinib sufficient to
achieve a positive completion and risks related to the potential
failure of cabozantinib to demonstrate safety and efficacy in
clinical testing; Exelixis’ dependence on its relationship with
Ipsen, including, the level of Ipsen’s investment in the resources
necessary to successfully commercialize cabozantinib in the
territories where it is approved; Exelixis’ dependence on its
relationship with Genentech/Roche with respect to cobimetinib and
Exelixis’ ability to maintain its rights under the collaboration;
Exelixis’ dependence on third-party vendors; Exelixis’ ability to
protect the company’s intellectual property rights; market
competition; changes in economic and business conditions, and other
factors discussed under the caption “Risk Factors” in Exelixis’
quarterly report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) on November 3, 2016, and in Exelixis’
future filings with the SEC. The forward-looking statements made in
this press release speak only as of the date of this press release.
Exelixis expressly disclaims any duty, obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Exelixis’
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
Exelixis, the Exelixis logo, COMETRIQ and
COTELLIC are registered U.S. trademarks, and CABOMETYX is a U.S.
trademark.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161207005614/en/
Exelixis, Inc.Lindsay Treadway, 650-837-7522Public Affairs and
Advocacy Relationsltreadway@exelixis.comorFor Exelixis, Inc.Hal
Mackins, 415-994-0040hal@torchcomllc.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Sep 2023 to Sep 2024